TRIAMINIC-12 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Triaminic-12, and what generic alternatives are available?
Triaminic-12 is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in TRIAMINIC-12 is chlorpheniramine maleate; phenylpropanolamine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the chlorpheniramine maleate; phenylpropanolamine hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TRIAMINIC-12?
- What are the global sales for TRIAMINIC-12?
- What is Average Wholesale Price for TRIAMINIC-12?
Summary for TRIAMINIC-12
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 1 |
| Patent Applications: | 17 |
| DailyMed Link: | TRIAMINIC-12 at DailyMed |
Recent Clinical Trials for TRIAMINIC-12
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Strathclyde | Phase 2 |
US Patents and Regulatory Information for TRIAMINIC-12
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TRIAMINIC-12 | chlorpheniramine maleate; phenylpropanolamine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 018115-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
